rs2569190 — CD14 -159C>T

CD14 -159C>T — The Innate Immune Dimmer Switch

CD14 is the first responder to bacterial invasion. Expressed on the surface of monocytes and macrophages¹¹ monocytes and macrophages
the frontline phagocytic cells of innate immunity, CD14 acts as a co-receptor that binds lipopolysaccharide (LPS) — the potent endotoxin coating the outer membrane of every gram-negative bacterium in your gut, on your skin, and in the environment. Once CD14 captures LPS, it hands it off to TLR4/MD-2²² TLR4/MD-2
Toll-like receptor 4, the signal-transducing partner that fires the NF-κB inflammatory cascade, triggering cytokine release and the full inflammatory response to bacterial threats.

The -159C>T promoter variant (rs2569190, also reported as -260C>T depending on the transcription start site used) is one of the most studied functional SNPs in immunogenetics. It sits in a GC-box element in the CD14 promoter³³ GC-box element in the CD14 promoter
a transcription factor binding site ~159 base pairs upstream of the coding sequence and changes how much CD14 protein your immune cells produce. The variant is notable for driving one of the clearest gene-environment interactions in all of allergy research.

The Mechanism

The T allele (reported as A on the plus strand in genome files; the gene is on the minus strand of chromosome 5) is associated with a functional impact on CD14 transcription⁴⁴ functional impact on CD14 transcription
In vivo chromatin immunoprecipitation shows twice as much RNA polymerase II recruited to the T-allele haplotype, indicating stronger transcription initiation, though allele-specific transcript quantification finds similar mRNA output between haplotypes. The net result is that TT homozygotes have significantly higher circulating soluble CD14 (sCD14)⁵⁵ TT homozygotes have significantly higher circulating soluble CD14 (sCD14)
sCD14 is shed from monocyte surfaces and acts as a soluble pattern-recognition molecule extending LPS detection to cells that don't express membrane CD14. CC homozygotes produce less sCD14 and have a more muted basal response to bacterial endotoxin.

This expression difference creates the paradox at the heart of the hygiene hypothesis: higher CD14 = more efficient LPS detection = stronger Th1 skewing = protection against allergic sensitization — but only when microbial exposure is high enough to exploit that capacity. In environments with low endotoxin load (urban living, formula feeding, no farm exposure), the T allele's higher CD14 expression may paradoxically drive heightened allergic responses by amplifying immune reactivity without the Th1-steering effect that requires persistent bacterial stimulation.

The Evidence

Baldini et al. 1999⁶⁶ Baldini et al. 1999
Original discovery in 481 children: TT homozygotes had significantly higher sCD14 and lower total IgE among skin-test-positive children (p=0.004) established that the T allele of CD14/-159 is the higher-expression variant and reduces IgE-mediated sensitization — but only in atopic children, implying a gene-environment gate.

The gene-environment interaction was definitively demonstrated by Simpson A et al. 2006⁷⁷ Simpson A et al. 2006
Study of 442 Manchester children showing opposite CD14 allele effects depending on farming exposure. In children with low endotoxin exposure, the C allele (GG genotype on plus strand) was the allergy risk genotype. In children with high endotoxin exposure (farm families), the T allele (AA on plus strand) became the risk genotype. The crossover was replicated across four independent populations (rural Europe, Manchester, Detroit, Barbados), with the most dramatic crossover effects seen in the high-contrast exposure settings.

A meta-analysis of 23 studies including 4,780 cases and 5,650 controls⁸⁸ A meta-analysis of 23 studies including 4,780 cases and 5,650 controls
BMC Medical Genetics 2011, PMID 21745379 found that when restricted to homogeneous atopic asthma phenotypes, the T allele is protective: TT vs CC OR = 0.67 (95% CI 0.54-0.84) and CT vs CC OR = 0.80 (95% CI 0.66-0.95), consistent with a codominant protective effect — in populations without stratification by endotoxin exposure.

Kerkhof et al. 2012⁹⁹ Kerkhof et al. 2012
JACI, PMID 21996339 pooled three allergy-prevention intervention cohorts and showed the genotype determines whether reducing microbial exposure in infancy helps or harms: interventions that decreased indoor allergen/endotoxin exposure were protective in CC children but increased atopy in TT children — a striking pharmacogenomic-style genotype-determines- direction effect.

For infectious disease, the T allele (AA genotype) consistently shows survival advantage. Mansur et al. 2015¹⁰¹⁰ Mansur et al. 2015
Prospective cohort of 417 sepsis patients, PMID 26020644 found that C-allele carriers had 23% 30-day mortality vs 13% for TT homozygotes, with the C allele remaining a significant independent covariate in multivariate Cox regression (HR 2.11, 95% CI 1.08-4.12, p=0.028). Higher sCD14 from the T allele appears to improve LPS clearance and dampen the cytokine storm cascade driving organ failure.

Conversely, for SARS-CoV-2, Pati et al. 2021¹¹¹¹ Pati et al. 2021
JID, PMID 33822099 found the T allele (higher CD14 expression) correlates with higher COVID-19 infection rates and mortality across European countries (r=0.57 and r=0.61 respectively), while the CC genotype was protective against severe SARS. This is consistent with the hygiene-hypothesis model: high CD14 may amplify inflammatory responses to novel viral-associated LPS signals or drive excessive innate immune activation.

Practical Actions

The actionable takeaway from this literature is not "which allele is good" — both have context-dependent advantages — but rather understanding how your genotype interacts with your microbial environment. GG (CC in papers) carriers benefit most from increasing microbial diversity; their lower-expression CD14 means they need richer bacterial stimulation to drive appropriate Th1 immune development and LPS tolerance. AA (TT) carriers already produce abundant CD14 and may be more sensitive to both high endotoxin environments and novel inflammatory triggers. For sepsis prevention, AA carriers appear inherently more resilient. For allergy prevention in low-endotoxin environments, GG carriers are at higher baseline risk and benefit most from microbial exposure strategies.

Probiotic strain selection matters for this SNP. Gram-negative probiotics and fermented foods containing LPS-like molecules (e.g. Bifidobacterium species, spore-forming Firmicutes) stimulate the CD14/TLR4 axis differently than gram-positive species with lipoteichoic acid. For GG carriers building Th1 tolerance, gram-negative-rich fermented foods provide endotoxin-tolerizing stimulation without excessive inflammatory drive.

Interactions

The most important interaction is with TLR4 (rs4986790, Asp299Gly)¹²¹² TLR4 (rs4986790, Asp299Gly)
TLR4 is the downstream signal transducer for LPS delivered by CD14. CD14 captures LPS and hands it to TLR4; variants in both genes affect the same LPS-sensing pathway and may have compounded effects. Individuals with low-CD14 expression (GG at rs2569190) combined with blunted TLR4 signaling (Asp299Gly at rs4986790) would have doubly impaired LPS recognition.

IL-1β (rs16944)¹³¹³ IL-1β (rs16944)
a downstream cytokine produced after TLR4 activation and [TNF-α (rs1800629) | another key effector cytokine in the LPS response] polymorphisms modify the magnitude of the downstream inflammatory response once CD14-mediated LPS recognition occurs. Combined low-CD14 (GG) with high-TNF (rs1800629 AA) may create discordant signaling — poor initial sensing but exaggerated response once threshold is crossed.

For the allergy interaction: the hygiene hypothesis gene-environment effect is most pronounced for TLR2 and TLR4 co-variants. Studies suggest that the farming protective effect on allergy operates through the CD14-TLR4-IL-12 axis, and variants in any of these genes modulate how robustly farm environments suppress IgE responses.